Nykredit Realkredit A/S
17.3.2021 08:51:22 CET | Globenewswire | Press release
To Nasdaq Copenhagen
17 March 2021
Nykredit Realkredit A/S – New final terms for Euro Medium Term Note Programme
Nykredit Realkredit A/S publishes final terms for an issue of EUR 50,000,000 0.01% Senior Non-Preferred Notes due 2024, which are issued pursuant to Nykredit Realkredit A/S's and Nykredit Bank A/S’s €10,000,000,000 Euro Medium Term Note Programme dated 13 May 2020.
The final terms dated 17 March 2021 and the EMTN Programme dated 13 May 2020 are available for download on Nykredit's website at nykredit.com/ir.
Enquiries may be addressed to Nykredit Realkredit A/S, Nicolaj Verdelin, Head of Funding Trading, Funding & Capital, tel +45 44 55 11 25, or Morten Bækmand Niel-sen, Head of Investor Relations, tel +45 44 55 15 21.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
CGTN19.9.2026 08:41:28 CEST | Press release
CGTN:CGTN Poll | Why is the SCO Solution for Global Governance Drawing Wide Attention?
Teva Pharmaceutical Industries Ltd18.9.2026 22:32:00 CEST | Press release
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Teva Pharmaceutical Industries Ltd18.9.2026 22:31:00 CEST | Press release
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
Teva Pharmaceutical Industries Ltd18.9.2026 22:30:00 CEST | Press release
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
Leading Edge Materials Corp.18.9.2026 20:30:00 CEST | Press release
LEADING EDGE MATERIALS REPORTS QUARTERLY RESULTS TO JULY 31, 2026 AND ANNOUNCES CLOSING OF THE SECOND TRANCHE OF PRIVATE PLACEMENT
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
